When was Orum Therapeutics founded?

Orum Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Orum Therapeutics located?

Orum Therapeutics is headquartered in Daejeon, South Korea.

How many employees does Orum Therapeutics have?

As of Aug 31, 2026, the latest employee count at Orum Therapeutics is 56.

Is Orum Therapeutics a funded company?

Orum Therapeutics is a funded company, having raised a total of $92M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 14, 2017.

When was the latest funding round of Orum Therapeutics?

Orum Therapeutics' latest funding was a $***** Post IPO round on Dec 18, 2025, with participation from 10 investors. Its primary sector is Immunotherapy. In South Korea, the Immunotherapy sector has seen $35.9M in funding in 2026 to date.

Where does Orum Therapeutics rank among its competitors?

Orum Therapeutics ranks 153rd amongst 3372 active competitors, of which 1136 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Orum Therapeutics?

Orum Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Orum Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Orum Therapeutics is a public company based in Daejeon (South Korea), founded in 2016 by Yong Sung Kim. It operates as a Developer of cell-penetrating antibodies as oncology therapeutics. Orum Therapeutics has raised $92M in funding from investors like IMM Investment, KTB Network and Smile Gate Investment. The company has 3372 active competitors, including 1136 funded and 786 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of cell-penetrating antibodies as oncology therapeutics. It has a proprietary cell-penetrating antibody technology and is developing monoclonal antibodies to directly target the activated form of RAS. The cell-penetrating technology develops antibodies that can access the cytosol of living cells following receptor-mediated endocytosis. RAS proteins function to transmit signals within cells that control cell growth, differentiation, and survival. The product pipeline includes ORM-5029, ORM-6151, and ANDC-0001 for solid tumors and hematological cancers

Website: www.orumrx.com/
Social

Key Metrics

Founded Year

2016

Location

Daejeon, South Korea

Stage

Public

Total Funding

$92M in 4 rounds

Latest Funding Round

Post IPO, Dec 18, 2025, $*****

Investors

IMM Investment & 20 more

Ranked

153^rd among 3372 active competitors

Employee Count

56 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3064 more

Exit Details

Public

View Orum Therapeutics' full profile

Orum Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ORUM THERAPEUTICS USA, INC. CIN: 833300238 , United States, Active	Dec 31, 1999	-	23 (As on Dec 31, 2024)	-
Orum Therapeutic Co., Ltd. CIN: 887-81-00503 , South Korea, Active	Aug 16, 2016	-	-	-

Orum Therapeutics got listed on Feb 14, 2025.

Click here to take a look at Orum Therapeutics's IPO in detail

Orum Therapeutics has raised a total funding of $92M over 4 rounds. Its first funding round was on Jun 14, 2017. Its latest funding round was a Post IPO round on Dec 18, 2025 for $*****. 10 investors participated in its latest round. Orum Therapeutics has 21 institutional investors.

Here is the list of recent funding rounds of Orum Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 18, 2025	6068938	Post IPO	4037506	2132314	4877691	9918240
Jun 23, 2021	8982756	Series B	2818876	4482987	4219589	KDB Investment & 3 more
Jul 17, 2019	2362288	Series B	9658653	8375932	IMM Investment & 3 more	Solidus Investment & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Orum Therapeutics's funding rounds and investors

The founders of Orum Therapeutics is Yong Sung Kim.

Here are the details of Orum Therapeutics' key team members:

Yong Sung Kim: Co-Founder of Orum Therapeutics.

View details of Orum Therapeutics's Founder profiles and Board Members

Orum Therapeutics' employee count trend

Orum Therapeutics has 56 employees as of Aug 26. Here is Orum Therapeutics's employee count trend over the years:

Employee count trend for Orum Therapeutics

Uncover Orum Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orum Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Orum Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
153rd	Orum Therapeutics 2016, Daejeon (South Korea), Public	Developer of cell-penetrating antibodies as oncology therapeutics	$92M	Weiss Asset Management, Aon & 19 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Orum Therapeutics's competitors? Click here to see the top ones

Orum Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Orum Therapeutics's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Orum Therapeutics

Media has covered Orum Therapeutics for a total of 9 events in the last 1 year, 4 of them have been about company updates and 3 about people movement.